

chain nodes :

12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

ring nodes :

1 2 3 4 5 6 7 8 9 10 11

chain bonds :

1-11 2-20 3-19 4-12 6-13 7-22 7-33 8-14 8-23 9-15 9-24 11-21 12-17 12-18
14-25 15-16 25-26 25-31 26-27 26-30 26-32 27-28 27-29

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11

exact/norm bonds :

1-2 1-6 1-11 2-3 3-4 4-5 4-12 5-6 6-13 7-8 7-11 7-33 8-9 8-14 9-10 10-11
14-25 25-31 26-30

exact bonds :

2-20 3-19 7-22 8-23 9-15 9-24 11-21 12-17 12-18 15-16 25-26 26-27 26-32 27-28
27-29

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS
30:CLASS 31:CLASS 32:CLASS 33:CLASS

Connecting via Winsock to STN

10/607,909

Welcome to STN International! Enter x:x

LOGINID:sssptal600txm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
USPAT2
NEWS 4 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 5 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
INPADOC
NEWS 6 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 7 JAN 17 IPC 8 in the WPI family of databases including WPIFV
NEWS 8 JAN 30 Saved answer limit increased
NEWS 9 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist
visualization results
NEWS 10 FEB 22 The IPC thesaurus added to additional patent databases on STN
NEWS 11 FEB 22 Updates in EPFULL; IPC 8 enhancements added
NEWS 12 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 13 FEB 28 MEDLINE/LMEDLINE reload improves functionality
NEWS 14 FEB 28 TOXCENTER reloaded with enhancements
NEWS 15 FEB 28 REGISTRY/ZREGISTRY enhanced with more experimental spectral
property data
NEWS 16 MAR 01 INSPEC reloaded and enhanced
NEWS 17 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 18 MAR 08 X.25 communication option no longer available after June 2006
NEWS 19 MAR 22 EMBASE is now updated on a daily basis
NEWS 20 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 21 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC
thesaurus added in PCTFULL
NEWS 22 APR 04 STN AnaVist \$500 visualization usage credit offered
NEWS 23 APR 12 LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 24 APR 12 Improved structure highlighting in FQHIT and QHIT display
in MARPAT
NEWS 25 APR 12 Derwent World Patents Index to be reloaded and enhanced during
second quarter; strategies may be affected

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:20:20 ON 26 APR 2006

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 12:20:40 ON 26 APR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 APR 2006 HIGHEST RN 881879-55-6

DICTIONARY FILE UPDATES: 25 APR 2006 HIGHEST RN 881879-55-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>


Uploading C:\Program Files\Stnexp\Queries\10607909.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss sam
SAMPLE SEARCH INITIATED 12:21:01 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      13 TO ITERATE

100.0% PROCESSED      13 ITERATIONS      0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:   44 TO      476
PROJECTED ANSWERS:      0 TO      0

L2      0 SEA SSS SAM L1
```

```
=> s l1 sss full
FULL SEARCH INITIATED 12:21:14 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      233 TO ITERATE

100.0% PROCESSED      233 ITERATIONS      29 ANSWERS
SEARCH TIME: 00.00.01


L3      29 SEA SSS FUL L1
```

```
=> d scan


L3      29 ANSWERS  REGISTRY  COPYRIGHT 2006 ACS on STN
IN      L-Valine, 3'-ester with 2'-C-methylcytidine, acetate (salt) (9CI)
MF      C15 H24 N4 O6 . x C2 H4 O2

CM      1
```

Absolute stereochemistry.



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

167.38

167.59

FILE 'CAPLUS' ENTERED AT 12:21:37 ON 26 APR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Apr 2006 VOL 144 ISS 18

FILE LAST UPDATED: 25 Apr 2006 (20060425/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13

L4 8 L3

=> d bib abs hitstr 1-8 14

L4 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:149315 CAPLUS

DN 144:205728

TI Methods using a Type II interferon receptor agonist alone or in combination with a direct antiviral drug for treating hepatitis C virus infection

IN Blatt, Lawrence M.

PA Intermune, Inc., USA

SO PCT Int. Appl., 139 pp.

CODEN: PIXXD2

DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006016930	A2	20060216	WO 2005-US16927	20050513
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI US 2004-571322P P 20040514

AB The invention provides methods for treating hepatitis C virus (HCV) infection; methods for reducing the incidence of complications associated with HCV and cirrhosis of the liver; and methods for reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clin. outcomes, in patients suffering from HCV infection. The methods generally involve administering to the individual a Type II interferon receptor agonist alone or in combination with a direct antiviral drug.

IT 640725-71-9, NM 283


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(type II interferon receptor agonist alone or in combination with direct antiviral drug for treating hepatitis C virus infection)

RN 640725-71-9 CAPLUS

CN L-Valine, 3'-ester with 2'-C-methylcytidine, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

L4 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:684531 CAPLUS

DN 143:431740

TI Emerging drugs for chronic hepatitis C

AU Bhopale, Girish Mahadeorao; Nanda, Rabindra Kumar

CS Research and Development Division, Hindustan Antibiotics Limited, Pimpri, Pune, 411018, India

SO Hepatology Research (2005), 32(3), 146-153

CODEN: HPRSFM; ISSN: 1586-6346

PB Elsevier B.V.

DT Journal; General Review

LA English

AB A review. Hepatitis C virus (HCV) is a major cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma worldwide. A combination therapy comprising pegylated interferon and ribavirin currently represents

the most effective therapy for chronic HCV infection. The limitations of this current therapy mainly its efficacy and significant side effects have prompted the development of new drugs. Few categories of therapeutic agents appear promising for future therapy, e.g. novel interferons, ribavirin analogs, antisense oligonucleotides, short interfering RNAs, ribozymes, enzyme inhibitors, immunomodulatory agents, antifibrotic agents, therapeutic vaccines and antibodies. Few drugs belong to afore-mentioned categories have already reached the different clin. phases of development. The present article highlights the status of current available therapies and emerging drugs for the treatment of hepatitis C.

IT 640725-71-9, NM 283


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(NM283 proved promising therapeutic effect in treating chronic hepatitis C patient)

RN 640725-71-9 CAPLUS

CN L-Valine, 3'-ester with 2'-C-methylcytidine, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RE.CNT 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:216597 CAPLUS

DN 142:291323

TI Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)

IN Hardee, Greg; Dellamary, Luis

PA Isis Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 217 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020885	A2	20050310	WO 2004-US16196	20040521
WO 2005020885	A3	20050804		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-472774P P

AB The invention provides compounds and methods for treating a coronavirus

infection, especially a SARS CoV infection. The compns. comprise an antiviral nucleoside or mimetic thereof, or an antiviral antisense agent, in a form suitable for pulmonary or nasal delivery. The methods comprise administration to a patient in need thereof the effective amount of an antiviral composition by pulmonary or nasal instillation.


IT 640281-90-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. and methods for treatment of severe acute respiratory syndrome)

RN 640281-90-9 CAPLUS

CN L-Valine, 3'-ester with 2'-C-methylcytidine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:515518 CAPLUS

DN 141:38814

TI Process for the production of 2'-branched nucleosides

IN Storer, Richard; Moussa, Adel; Chaudhuri, Narayan; Waligora, Frank

PA Idenix Cayman Limited, Cayman I.

SO PCT Int. Appl., 90 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004052899	A2	20040624	WO 2003-US39643	20031212
	WO 2004052899	A3	20050331		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2509687	AA	20040624	CA 2003-2509687	20031212
	US 2005020825	A1	20050127	US 2003-735408	20031212
	EP 1585529	A2	20051019	EP 2003-812993	20031212
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	CN 1744903	A	20060308	CN 2003-80109576	20031212
	NO 2005003115	A	20050818	NO 2005-3115	20050624
PRAI	US 2002-432766P	P	20021212		
	US 2003-466194P	P	20030428		
	WO 2003-US39643	W	20031212		
OS	CASREACT 141:38814				
GI					




AB The present invention provides an improved process for preparing ss-D and ss-L 2'-C-methyl-nucleosides and 2'-C-methyl-3'-O-ester nucleosides, e.g. I, via glycosylation of methylribonolactone with nucleobases.

IT 640725-71-9P
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (process for production of 2'-branched nucleosides via glycosylation of methylribonolactone with nucleobases)

RN 640725-71-9 CAPLUS

CN L-Valine, 3'-ester with 2'-C-methylcytidine, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:453348 CAPLUS

DN 141:17578

TI Treatment of Flaviviridae infection with 2'-branched nucleosides and another mutation-inducing drug such as interferon

IN Sommadosi, Jean-Pierre; La Colla, Paolo; Standring, David; Bichko, Vadim; Qu, Lin

PA Idenix (Cayman) Limited, Cayman I.; Universita Degli Studi Di Cagliari

SO PCT Int. Appl., 166 pp.
 CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004046331	A2	20040603	WO 2003-US36714	20031117
	WO 2004046331	A3	20060302		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,				

TN, TR, TT, TZ, UA, UG, US, UZ, VG, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2506129 AA 20040603 CA 2003-2506129 20031117
 US 2005031588 A1 20050210 US 2003-715729 20031117
 EP 1576138 A2 20050921 EP 2003-796412 20031117

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR 2003016363 A 20051004 BR 2003-16363 20031117
 NO 2005002920 A 20050815 NO 2005-2920 20050615

PRAI US 2002-426675P P 20021115
 WO 2003-US36714 W 20031117

OS MARPAT 141:17578

AB The present invention discloses a method for the treatment of Flaviviridae infection that includes the administration of a 2'-branched nucleoside, or a pharmaceutically acceptable prodrug and/or salt thereof, to a human in need of therapy in combination or alternation with a drug that directly or indirectly induces a mutation in the viral genome at a location other than a mutation of a nucleotide that results in a change from serine to a different amino acid in the highly conserved consensus sequence, XRX<u>S</u>GXXXT, of domain B of the RNA polymerase region, or is associated with such a mutation. The invention also includes a method to detect a mutant strain of Flaviviridae and a method for its treatment. Thus, in bovine viral diarrhea virus (BVDV)-infected MDBK cells treated with β -D-2'-methylcytidine, viruses resistant to the nucleoside appeared. The drug resistance was associated with a mutation in the NS5B gene which resulted in an S405T substitution in the encoded RNA-dependent RNA polymerase. These mutant viruses were sensitive to Intron A (interferon α -2b). Intron A and β -D-2'-methylcytidine exhibited synergistic inhibitory activity on BVDV growth in MDBK cells.


IT 640281-90-9

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (treatment of Flaviviridae infection with 2'-branched nucleosides and another mutation-inducing drug such as interferon)

RN 640281-90-9 CAPLUS

CN L-Valine, 3'-ester with 2'-C-methylcytidine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:20697 CAPLUS

DN 140:87662

TI 2'- and 3'-nucleoside prodrugs for treating Flaviviridae infections

IN Sommadossi, Jean-pierre; La Colla, Paolo; Storer, Richard; Gosselin, Gilles

PA Idenix (Cayman) Limited, Cayman I.; Centre National de la Recherche Scientifique; Universita Degli Studi di Cagliari

SO PCT Int. Appl., 2498 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

PI	WO 2004003000	A2	20040108	WO 2003-IB3901	20030627
	WO 2004003000	A3	20041104		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2490200	AA	20040108	CA 2003-2490200	20030627
	AU 2003263412	A1	20040119	AU 2003-263412	20030627
	EP 1525209	A2	20050427	EP 2003-761749	20030627
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005537242	T2	20051208	JP 2004-517162	20030627
	CN 1761677	A	20060419	CN 2003-820501	20030627
	WO 2005020884	A2	20050310	WO 2004-US15395	20040514
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	NO 2005000466	A	20050323	NO 2005-466	20050127
PRAI	US 2002-392350P	P	20020628		
	US 2002-392351P	P	20020628		
	US 2003-466194P	P	20030428		
	US 2003-470949P	P	20030514		
	WO 2003-IB3901	W	20030627		
OS	MARPAT 140:87662				
AB	2' And 3'-Prodrugs of 1'-, 2'-, 3'-, or 4'-branched β -D or β -L nucleosides, or their pharmaceutically acceptable salts and derivs., are described which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior results against flaviviruses and pestiviruses, including hepatitis C virus and viruses generally that replicate through an RNA-dependent RNA reverse transcriptase. Compds., compns., methods and uses are provided for the treatment of Flaviviridae infection, including HCV infection, that include the administration of an effective amount of the prodrugs of the invention, or their pharmaceutically acceptable salts or derivs. These drugs may optionally be administered in combination or alternation with further antiviral agents to prevent or treat Flaviviridae infections and other related conditions. Preparation of compds. of the invention is included.				
IT	640725-71-9P				
	RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(nucleoside prodrugs for treating Flaviviridae infections)				
RN	640725-71-9 CAPLUS				
CN	L-Valine, 3'-ester with 2'-C-methylcytidine, dihydrochloride (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



L4 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:20696 CAPLUS
 DN 140:77365
 TI Preparation of modified 2'- and 3'-nucleoside prodrugs for treating
 Flaviviridae infections
 IN Sommadossi, Jean-pierre; La Colla, Poalo; Storer, Richard; Gosselin,
 Gilles
 PA Idenix (Cayman) Limited, Cayman I.; Universita degli studi di Cagliari;
 Centre National de la Recherche Scientifique
 SO PCT Int. Appl., 201 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004002999	A2	20040108	WO 2003-IB3246	20030627
	WO 2004002999	A3	20040812		
	WO 2004002999	C1	20050217		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2490191	AA	20040108	CA 2003-2490191	20030627
	AU 2003247084	A1	20040119	AU 2003-247084	20030627
	EP 1523489	A2	20050420	EP 2003-761744	20030627
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005533817	T2	20051110	JP 2004-517158	20030627
	CN 1761677	A	20060419	CN 2003-820501	20030627
	WO 2005020884	A2	20050310	WO 2004-US15395	20040514
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SI, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	NO 2005000465	A	20050127	NO 2005-465	20050127
PRAI	US 2002-392350P	P	20020628		
	US 2002-392351P	P	20020628		
	US 2003-466194P	P	20030428		

OS
GI



AB 2' And/or 3' prodrugs of 1', 2', 3' or 4'-branched-nucleosides I, wherein R1-R3 are independently H, phosphate, alkyl, acyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, sulfonate ester, benzyl, wherein the Ph group is optionally substituted with one or more substituents, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, lipid, amino acid, carbohydrate, peptide, cholesterol; Y1 is hydrogen, bromo, chloro, fluoro, iodo, CN, OH, OR4, NH2, NHR4, NR4R5, SH or SR4; X1 and X2 are independently alkyl, CH3, CF3, CY3, 2-Br-Et, CH2F, CH2Cl, CH2CF3, CF2CF3, CY2CY3, CH2OH, alkenyl, alkynyl, COOH, COOR4, COO-alkyl, COO-aryl, CO-O-alkoxyalkyl, CONH2, CONHR4, CON(R4)2, halo, CN, N3, OH, OR4, NH2, NHR4, NR4R5, SH or SR5; Y is independently H, halo; and each R4 and R5 is independently hydrogen, acyl, alkyl, lower alkyl, alkenyl, alkynyl or cycloalkyl, and their pharmaceutically acceptable salts and derivs. are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Comps. and compns. of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivs. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions. Thus, antiviral activity of β -D-2'-C-methyl-7-methyl-6-phenyl-3,3a,5,8a-tetrahydro-1,3,4,5,7a-penta-aza-s-indacen-8-one is reported.


IT 640281-90-9P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of modified and nucleoside prodrugs for treating flaviviridae infections)

RN 640281-90-9 CAPLUS

CN L-Valine, 3'-ester with 2'-C-methylcytidine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:20443 CAPLUS

DN 140:70984

TI 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections

IN Sommadossi, Jean-Pierre; La Colla, Paolo

PA Idenix (Cayman) Limited, Cayman I.; Universita Degli Studi di Cagliari

SO PCT Int. Appl., 110 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

NY App

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004002422	A2	20040108	WO 2003-US20431	20030627
	WO 2004002422	A3	20050407		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2489552	AA	20040108	CA 2003-2489552	20030627
	US 2004077587	A1	20040422	US 2003-607909	20030627
	EP 1536804	A2	20050608	EP 2003-762183	20030627
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2005533824	T2	20051110	JP 2004-518041	20030627
	WO 2005020884	A2	20050310	WO 2004-US15395	20040514
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	NO 2005000490	A	20050127	NO 2005-490	20050127
PRAI	US 2002-392351P	P	20020628		
	US 2003-466194P	P	20030428		
	US 2003-470949P	P	20030514		
	WO 2003-US20431	W	20030627		

OS MARPAT 140:70984

AB The 3'-L-valine ester of β -D-2'-C-methyl-ribofuranosyl cytidine provides superior results against flaviviruses and pestiviruses, including hepatitis C virus. Based on this discovery, compds., compns., methods and uses are provided for the treatment of flaviviridae, including HCV, that include the administration of an effective amount of val-mCyd or its salt, ester, prodrug or derivative, optionally in a pharmaceutically acceptable carrier. In an alternative embodiment, val-mCyd is used to treat any virus that replicates through an RNA-dependent RNA polymerase. Several examples are provided of the pharmacol., mechanism of action, metabolism, side effects, and clin. efficacy of the title compound

IT 640281-90-9D, salts 642075-50-1 642075-51-2

642075-52-3 642075-53-4 642075-54-5

642075-55-6 642075-56-7 642075-57-8

642075-58-9 642075-59-0 642075-60-3

642075-61-4 642075-62-5 642075-63-6

642075-64-7 642075-65-8 642075-66-9

642075-67-0 642075-68-1 642075-69-2

642075-70-5 642075-71-6 642075-72-7

642075-74-9 642075-75-0 642075-76-1


642075-77-2

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ribofuranosylcytidine methylvaline ester combined with other
antivirals for treatment of flaviviridae infections)

RN 640281-90-9 CAPLUS

CN L-Valine, 3'-ester with 2'-C-methylcytidine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 642075-50-1 CAPLUS


CN L-Valine, 3'-ester with 2'-C-methylcytidine, 4-methylbenzenesulfonate
(salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9

CMF C15 H24 N4 O6


Absolute stereochemistry.



CM 2

CRN 104-15-4

CMF C7 H8 O3 S



RN 642075-51-2 CAPLUS


CN L-Valine, 3'-ester with 2'-C-methylcytidine, methanesulfonate (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 640281-90-9

CMF C15 H24 N4 O6


Absolute stereochemistry.



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 642075-52-3 CAPLUS


CN L-Valine, 3'-ester with 2'-C-methylcytidine, acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9

CMF C15 H24 N4 O6


Absolute stereochemistry.



CM 2

CRN 64-19-7

CMF C2 H4 O2



RN 642075-53-4 CAPLUS


CN L-Valine, 3'-ester with 2'-C-methylcytidine, 2-hydroxy-1,2,3-propanetricarboxylate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9

CMF C15 H24 N4 O6


Absolute stereochemistry.



CM 2

CRN 77-92-9

CMF C6 H8 O7



RN 642075-54-5 CAPLUS


CN L-Valine, 3'-ester with 2'-C-methylcytidine, propanedioate (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 640281-90-9

CMF C15 H24 N4 O6


Absolute stereochemistry.



CM 2

CRN 141-82-2

CMF C3 H4 O4




RN 642075-55-6 CAPLUS

CN L-Valine, 3'-ester with 2'-C-methylcytidine, (2R,3R)-2,3-dihydroxybutanedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6


Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.




RN 642075-56-7 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, butanedioate (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 110-15-6
CMF C4 H6 O4


HO2C-CH2-CH2-CO2H

RN 642075-57-8 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, benzoate (salt) (9CI) (CA
INDEX NAME)

CM 1


CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 65-85-0
CMF C7 H6 O2




RN 642075-58-9 CAPLUS
CN L-Ascorbic acid, compd. with L-valine 3'-ester with 2'-C-methylcytidine
(9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6


Absolute stereochemistry.



CM 2

CRN 50-81-7
CMF C6 H8 O6

Absolute stereochemistry.




RN 642075-59-0 CAPLUS
 CN L-Valine, 3'-ester with 2'-C-methylcytidine, 2-oxopentanedioate (salt)
 (9CI) (CA INDEX NAME)

CM 1


CRN 640281-90-9
 CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 328-50-7
 CMF C5 H6 O5




RN 642075-60-3 CAPLUS
 CN L-Valine, 3'-ester with 2'-C-methylcytidine, 2,3-dihydroxypropyl phosphate
 (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 640281-90-9
 CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 57-03-4
CMF C3 H9 O6 P




RN 642075-61-4 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, formate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2




RN 642075-62-5 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, (2E)-2-butenedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6


Absolute stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 642075-63-6 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, propanoate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 79-09-4
CMF C3 H6 O2




RN 642075-64-7 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, hydroxyacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 79-14-1
CMF C2 H4 O3




RN 642075-65-8 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, 2-hydroxypropanoate (salt)
(9CI) (CA INDEX NAME)

CM 1


CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 50-21-5
CMF C3 H6 O3




RN 642075-66-9 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, 2-oxopropanoate (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6


Absolute stereochemistry.



CM 2

CRN 127-17-3

CMF C3 H4 O3



RN 642075-67-0 CAPLUS


CN L-Valine, 3'-ester with 2'-C-methylcytidine, ethanedioate (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 640281-90-9

CMF C15 H24 N4 O6


Absolute stereochemistry.



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 642075-68-1 CAPLUS


CN L-Valine, 3'-ester with 2'-C-methylcytidine, (2Z)-2-butenedioate (salt)
(9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9

CMF C15 H24 N4 O6

Absolute stereochemistry.




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 642075-69-2 CAPLUS


CN L-Valine, 3'-ester with 2'-C-methylcytidine, 2-hydroxybenzoate (salt)
(9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9

CMF C15 H24 N4 O6


Absolute stereochemistry.



CM 2

CRN 69-72-7

CMF C7 H6 O3



RN 642075-70-5 CAPLUS


CN L-Valine, 3'-ester with 2'-C-methylcytidine, sulfate (salt) (9CI) (CA
INDEX NAME)

CM 1

CRN 640281-90-9

CMF C15 H24 N4 O6


Absolute stereochemistry.



CM 2

CRN 7664-93-9

CMF H2 O4 S



RN 642075-71-6 CAPLUS


CN L-Valine, 3'-ester with 2'-C-methylcytidine, nitrate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9

CMF C15 H24 N4 O6


Absolute stereochemistry.



CM 2

CRN 7697-37-2

CMF H N O3



RN 642075-72-7 CAPLUS


CN L-Valine, 3'-ester with 2'-C-methylcytidine, carbonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9

CMF C15 H24 N4 O6


Absolute stereochemistry.



CM 2.

CRN 463-79-6


CMF C H2 O3



RN 642075-74-9 CAPLUS

CN L-Valine, 3'-ester with 2'-C-methylcytidine, hydrobromide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HBr

RN 642075-75-0 CAPLUS

CN L-Valine, 3'-ester with 2'-C-methylcytidine, hydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HI

RN 642075-76-1 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, carbonate (2:1) (salt) (9CI)
(CA INDEX NAME)

CM 1


CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 463-79-6
CMF C H2 O3




RN 642075-77-2 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, phosphate (salt) (9CI) (CA
INDEX NAME)

CM 1


CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P




IT 640281-90-9P

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(ribofuranosylcytidine methylvaline ester for treatment of flaviviridae infections)

RN 640281-90-9 CAPLUS

CN L-Valine, 3'-ester with 2'-C-methylcytidine (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 640725-71-9P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(ribofuranosylcytidine methylvaline ester for treatment of flaviviridae infections)

RN 640725-71-9 CAPLUS

CN L-Valine, 3'-ester with 2'-C-methylcytidine, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl